Acknowledgements
Nordisk A/S, Diabetes
DIABETES
The authors are grateful to N. R. Kristensen (Novo Nordisk A/S, Søborg, Denmark) for performing the pharmacokinetic modelling. Medical writing support was provided by C. Roepstorff (CR Pharma Consult, Copenhagen, Denmark), funded by Novo Nordisk. Some of the data were presented as an abstract at the American Diabetes Association 82nd Scientific Sessions in 2022 and at the 58th EASD Annual Meeting of the European Association for the Study of Diabetes in 2022.